Yeni Kuşak Antiepileptik İlaçlar
Özet
Bu çalışma, yeni nesil antiepileptik ilaçların (Brivaracetam, Lacosamide, Perampanel, Retigabin, Rufinamide, Stiripentol, Zonisamide ve Sulthiame) klinik kullanım alanlarını, farmakolojik özelliklerini ve etkileşim profillerini detaylıca ele almaktadır. Her bir ilacın etki mekanizmaları, onaylanan yaş grupları, yaygın kullanılan tedavi endikasyonları ve olası yan etki profilleri karşılaştırmalı verilerle incelenmiştir. İlaçların epilepsi sendromları ve dirençli nöbet tiplerindeki tedavi başarısı, mevcut güncel çalışmalarla desteklenerek sunulmaktadır. Özellikle ilaç etkileşimleri ve böbrek/karaciğer üzerindeki metabolik süreçler, klinik pratik için kritik bilgiler olarak vurgulanmıştır.
Referanslar
Kalss G, Rohracher A, Leitinger M, et al. Intravenous brivaracetam in status epilepticus: a retrospective single-center study. Epilepsia. 2018;59(Suppl 2):228–233.
Brigo F, Lattanzi S, Nardone R, et al. Intravenous Brivaracetam in the treatment of status epilepticus: a systematic review. CNS Drugs. 2019;33:771–781.
Liu E, Dilley D, McDonough B, et al. Safety and tolerability of adjunctive Brivaracetam in pediatric patients < 16 years with epilepsy: an open-label trial. Paediatr Drugs. 2019;21:291–301.
Brandt C, Klein P, Badalamenti V, et al. Safety and tolerability of adjunctive brivaracetam in epilepsy: in-depth pooled analysis. Epilepsy Behav. 2020;103:106864.
UCB Inc. VIMPAT (lacosamide): US prescribing information. 2017. http://www.fda.gov/. Accessed 20 Mar 2018.
Rosenow F, Kelemen A, Ben-Menachem E, et al. Long-term adjunctive lacosamide treatment in patients with partial-onset seizures. Acta Neurol Scand. 2015;133(2):136–44.
Toupin J-F, Lortie A, Major P, et al. Efficacy and safety of lacosamide as an adjunctive therapy for refractory focal epilepsy in paediatric patients: a retrospective single-centre study. Epileptic Disord. 2015;17(4):436–43.
Grosso S, Zamponi N, Bartocci A, Cesaroni E, Cappanera S, Di Bartolo R, et al. Lacosamide in children with refractory status epilepticus: a multicenter Italian experience. Eur J Paediatr Neurol 2014;18:604–8
Chang FM, Fan PC, Weng WC, Chang CH, Lee WT. The efficacy of perampanel in young children with drug-resistant epilepsy. Seizure. 2020 Feb;75:82-86. doi: 10.1016/j.seizure.2019.12.024. Epub 2019 Dec 23.
Maschio M, Zarabla A, Maialetti A, et al. Perampanel in brain tumor-related epilepsy: Observational pilot study. Brain Behav. 2020;10:e01612. https://doi.org/10.1002/brb3.1612
Potschka H, Trinka E. Perampanel: Does it have broad-spectrum potential? Epilepsia. 2018;00:1–15.
Singh NA et al (1998) A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 18:25–29
Shi, S., Li, J., Sun, F. et al. Molecular Mechanisms and Structural Basis of Retigabine Analogues in Regulating KCNQ2 Channel. J Membrane Biol 253, 167–181 (2020).
Gunthorpe MJ, Large CH, Sankar R (2012) The mechanism of action of retigabine (ezogabine), a first-in-class K + channel opener for the treatment of epilepsy. Epilepsia 53:412–424.
Panebianco M 1, Prabhakar H, Marson AG. Rufinamide add-on therapy for refractory epilepsy. Cochrane Database Syst Rev. 2018;4:CD011772.
Striano P, McMurray R, Santamarina E, Falip M. Rufinamide for the treatment of lennox-gastaut syndrome: evidence from clinical trials and clinical practice. Epileptic Disord. 2018;20(1):13–29.
Cusmai R, Verrotti A, Moavero R, et al. Rufinamide for the treatment of refractory epilepsy secondary to neuronal migration disorders. Epilepsy Res. 2014;108(3):542–546.
Perez J, Chiron C, Musial C, Rey E, Blehaut H, d’Athis P, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia. 1999;40:1618–26.
Inoue Y, Ohtsuka Y, Group S-S. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: a multicenter, open-label study in Japan. Epilepsy Res. 2015;113:90–7.
Merdariu D, Delanoe C, Mahfoufi N, Bellavoine V, Auvin S. Malignant migrating partial seizures of infancy controlled by stiripentol and clonazepam. Brain Dev. 2013;35:177–80.
Strzelczyk A, Kortland LM, Knake S, Rosenow F. Stiripentol for the treatment of super-refractory status epilepticus. Acta Neuro Scand. 2015;132:435–9.
Nickels KC, Wirrell EC. Stiripentol in the Management of Epilepsy. CNS Drugs. 2017 May;31(5):405-416.
Seki T, Kumagai N, Maezawa M. Effects of zonisamide monotherapy in children with epilepsy. Seizure 2004;13(Suppl. 1): S26–32.
Brodie MJ. Zonisamide as adjunctive therapy for refractory partial seizures. Epilepsy Res 2006;68(Suppl. 2):S11–6.
Sackellares JC, Ramsay RE, Wilder BJ, Browne 3rd TR, Shellenberger MK. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 2004;45:610–7.
Engler F, Maeder-Ingvar M, Roulet E, Deonna T. Treatment of sulthiame in benign partial epilepsy of childhood and related syndromes: an open clinical and EEG study. Neuropediatrics 2003;34:105–9.
Lerman P, Lerman-Sagie T. Sulthiame revisited. J. Child Neurol. 1995; 10:241-2
Bresnahan_R, Martin-McGill_KJ, Milburn-McNulty_P, Powell_G, Sills_GJ, Marson_AG. Sulthiame add-on therapy for epilepsy. Cochrane Database of Systematic Reviews 2019, Issue 8. Art. No.: CD009472.
Eleonora Tulli, Giuseppe Di Cara, Giulia Iapadre, Pasquale Striano & Alberto Verrotti (2021): An update on brivaracetam for the treatment of pediatric partial epilepsy, Expert Opinion on Pharmacotherapy, DOI: 10.1080/14656566.2021.1921151
